PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: Visiongain

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Single-use Bioreactors Market will Expand this Decade Predicts Visiongain Report - A new report by visiongain forecasts that the world market for disposable bioreactor technology for pharmaceuticals will expand from 2012 to 2022 - Visiongain.com
Single-use Bioreactors Market will Expand this Decade Predicts Visiongain Report

 

NewswireToday - /newswire/ - London, United Kingdom, 2012/04/23 - A new report by visiongain forecasts that the world market for disposable bioreactor technology for pharmaceuticals will expand from 2012 to 2022 - Visiongain.com.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

That projection appears in Single-Use Bioreactors for Pharma: World Market 2012-2022, published in April 2012. Visiongain is a business information provider based in London, UK.

In the past 10 years, single-use bioprocess technologies have helped in the development and production of biopharmaceuticals. These technologies and accessories play important roles in early biopharma development and upstream processing, as well as commercial production of biomolecules. Their use will increase from 2012, the study notes.

Visiongain predicts that overall revenues from the technologies will show strong growth from 2012 to 2022, with many commercial opportunities arising. Single- and limited-use units (bioprocess disposables) are becoming more important in the development and production of biopharmaceuticals. There will be a shift away from traditional biomanufacturing systems as newer, more-convenient disposable systems reach the biopharma industry from 2012 onwards.

Dr Syed Ahmed, a senior healthcare industry analyst at visiongain, explains: “Most experts agree that single-use equipment will become widely available for end-to-end bioprocessing across all production scales. Estimates suggest that 50% of GMP production of biomolecules already uses disposable technologies. That trend will continue as these technologies mature and prove their cost effectiveness, especially for downstream operations.

“For single-use bioreactors, the industry expects a transition from manual to automated, smart, single-use bioreactor systems having feed based on real time in-situ measurements. Scale is no longer an issue; disposable bioreactors of 2000L capacity and higher are available to pharma companies. Biopharmaceutical producers seek to operate multiple (500-2000L) batches. Availability of high titres permits this and also reduces the risk of batch loss for manufacturers. Those trends make single-use bioreactors important for bioprocessing and GMP operations.”

The new report provides revenue forecasts to 2022 at world market, submarket and national level. Its research, data and analyses cover activities of GE Healthcare, Thermo Scientific, Sartorius Stedim and other providers of bioprocess technologies. In addition to forecasting the overall world market for the topic, the analysis predicts revenue trends for two main submarkets: hardware modules and systems; and disposables and accessories.

Visiongain’s investigation involves assessing R&D activities, interviewing authorities on the industry and predicting disposable bioreactor revenues in leading national markets. Countries analysed are the US, Japan, the EU5, China and India. Single-Use Bioreactors for Pharma: World Market 2012-2022 adds to visiongain’s range of analytical reports on industries and markets for pharmaceutical technologies.

For sample pages and further information concerning the visiongain report Single-Use Bioreactors for Pharma: World Market 2012-2022 please visit the website.

About visiongain
Visiongain (visiongain.com) is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, visiongain produces a host of business-2-business conferences, newsletters, management reports and e-zines focusing on the Energy, Telecoms, Pharmaceutical, Defence, Aviation and Materials sectors.

Visiongain publishes reports produced by its in-house analysts, who are qualified experts in their field. Visiongain has firmly established itself as the first port-of-call for the business professional, who needs independent, high quality, original material to rely and depend on.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: Visiongain

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Single-use Bioreactors Market will Expand this Decade Predicts Visiongain Report

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

|
Publisher Contact: Sara Peerun - Visiongain.com 
+44(0)20 7336 6100 sara.peerun[.]visiongain.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Visiongain securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From Visiongain / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

First Pulmonary Embolism Patients in Hong Kong Treated with the EKOS® System
Ipsen to Acquire Oncology Assets from Merrimack Pharmaceuticals
FDA Grants Genentech’s Cancer Immunotherapy Tecentriq® (Atezolizumab) Priority Review in Additional Type of Advanced Bladder Cancer
FDA Approves Genentech’s Lucentis® (Ranibizumab Injection) for Myopic Choroidal Neovascularization
Sugar Element of Keratan Sulfate Halts the Progress of Emphysema Finds RIKEN
Exelixis and Ipsen Amend Exclusive Licensing Agreement for the Commercialization and Development of Cabozantinib to Include Canada
FDA Extends Review of Application for OCREVUS™ (Ocrelizumab)
MDxHealth Announces AceCGT Life Science Limited as the Exclusive Distributor for SelectMDx in Hong Kong and Macao China
Pulse Certified As A Level Four Multichannel Content Agency by Veeva Systems
BD Launches Advanced Prefillable Syringe for Higher Volume Injection of Biologics
Sartorius Announces Expansion of Sartorius Stedim Cellca
Frost & Sullivan Commends Nemaura for Developing Superior Transdermal Drug Delivery Technology Platforms, the Memspatch and Micropatch
Greenphire Sponsors Second Annual Clinical Trial Agreements, Investigator Payments and Fair Market Value Meeting
BD Integrating Technology, Expertise and Services to Provide Comprehensive Medication Management
Genentech’s Gazyva Helped People with Previously Untreated Follicular Lymphoma Live Significantly Longer

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  La Bella Bakery Artisan Bakery Arizona

Visit  JobsWare.com





 
  ©2017 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)